Maria Maccecchini received her PhD in biochemistry from Rockefeller University and spent two years at Caltech as a postdoc in molecular biology. Her first industry position was at Mallickrodt as research scientist. Subsequently, she served as general manager of Bachem Bioscience, a US subsidiary of a Swiss company. In the early 1990s, Dr. Maccecchini established Symphony Pharmaceuticals. After acquiring the Scottish and Japanese company Cruachem, Symphony Pharmaceuticals changed its name to Annovis. Annovis develops, manufactures, and markets a variety of nucleic acid-based products and services for businesses in the life sciences sector. In 2001, Annovis was acquired by Transgenomic Inc. of San Jose, CA. Dr. Maccecchini serves on several boards of biotechnology companies, organizations that promote entrepreneurship, international trade as well as women and charitable organizations. Currently she is a member and director of two angel funds – Robin Hood Ventures and Mid-Atlantic Angel Group.
Current role